Press Releases Stay on top of the latest news from Poseida Therapeutics. Learn about our leading-edge cell and gene therapy programs, from new discoveries to clinical trials, and get the most recent investor news. IR Sub Menu Investors & Media Corporate Profile Press Releases Events & Presentations Publications Year None2021202020192018201720162015 Poseida Therapeutics to Host Virtual R&D Day on February 24, 2021 02/10/2021 Poseida Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Day 02/04/2021 Poseida Therapeutics to Participate in SternIR Virtual Corporate Access Event 01/04/2021 Poseida Therapeutics Added to NASDAQ Biotechnology Index 12/18/2020 Poseida Therapeutics Appoints Luke Corning to Board of Directors 12/17/2020 Poseida Therapeutics Provides Update on Phase 1 Trial of P-BCMA-101 at the 2020 American Society of Hematology Annual Meeting 12/05/2020 Poseida Therapeutics Reports Operational Update and Financial Results for Third Quarter 2020 11/12/2020 Poseida Therapeutics Announces Clinical Hold Lifted on Phase I Autologous CAR-T Study in Prostate Cancer 11/02/2020 Poseida Therapeutics and TScan Therapeutics Announce Research Collaboration and License Agreement to Explore Developing Allogeneic T Cell Receptor Therapies for the Treatment of COVID-19 10/21/2020 Poseida Therapeutics Added to Membership of US Small-Cap Russell 2000® Index 09/18/2020 Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Next page next › Last page last » Displaying 11 - 20 of 70
Year None2021202020192018201720162015 Poseida Therapeutics to Host Virtual R&D Day on February 24, 2021 02/10/2021 Poseida Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Day 02/04/2021 Poseida Therapeutics to Participate in SternIR Virtual Corporate Access Event 01/04/2021 Poseida Therapeutics Added to NASDAQ Biotechnology Index 12/18/2020 Poseida Therapeutics Appoints Luke Corning to Board of Directors 12/17/2020 Poseida Therapeutics Provides Update on Phase 1 Trial of P-BCMA-101 at the 2020 American Society of Hematology Annual Meeting 12/05/2020 Poseida Therapeutics Reports Operational Update and Financial Results for Third Quarter 2020 11/12/2020 Poseida Therapeutics Announces Clinical Hold Lifted on Phase I Autologous CAR-T Study in Prostate Cancer 11/02/2020 Poseida Therapeutics and TScan Therapeutics Announce Research Collaboration and License Agreement to Explore Developing Allogeneic T Cell Receptor Therapies for the Treatment of COVID-19 10/21/2020 Poseida Therapeutics Added to Membership of US Small-Cap Russell 2000® Index 09/18/2020 Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Next page next › Last page last » Displaying 11 - 20 of 70
Poseida Therapeutics Provides Update on Phase 1 Trial of P-BCMA-101 at the 2020 American Society of Hematology Annual Meeting 12/05/2020
Poseida Therapeutics Reports Operational Update and Financial Results for Third Quarter 2020 11/12/2020
Poseida Therapeutics Announces Clinical Hold Lifted on Phase I Autologous CAR-T Study in Prostate Cancer 11/02/2020
Poseida Therapeutics and TScan Therapeutics Announce Research Collaboration and License Agreement to Explore Developing Allogeneic T Cell Receptor Therapies for the Treatment of COVID-19 10/21/2020